The French passenger is on a machine that breathes for him. Inside a biocontainment ward at a Paris hospital, the man lies connected to an ECMO circuit, a device that pulls blood from the body, infuses it with oxygen, and pumps it back in when the lungs can no longer do the job. “His condition is critical,” the treating physician told the Associated Press, describing a patient fully dependent on artificial lung support. He is the sickest known survivor of an outbreak that began on an Antarctic cruise ship called the Hondius and has now scattered confirmed or probable infections across at least four countries, killing three people so far.
Across the Atlantic, 41 American passengers exposed to the same pathogen are under medical watch at high-security facilities in Nebraska and Atlanta. At least one U.S. test result remains unresolved. And the World Health Organization’s most recent count, updated May 13, 2026, stands at 11 confirmed or probable cases and three deaths, all linked to a single voyage.
What authorities have confirmed
The WHO received its first notification about the outbreak on May 2, 2026. Laboratory confirmation that the pathogen was Andes virus, a hantavirus found in South America and the only hantavirus known to spread person to person, followed on May 6, according to a CDC health alert. Initial PCR testing was performed in South Africa, where the Hondius had docked after medical evacuations forced the ship to cut its itinerary short.
By that point, many of the roughly 170 passengers aboard had already flown home to countries across Europe, North America, and beyond. Contact tracing became an intercontinental exercise almost immediately.
The French patient’s rapid decline illustrates one of the most unsettling features of Andes virus: its long, quiet incubation period can give way to sudden respiratory collapse. The European Centre for Disease Prevention and Control confirmed that the French case developed symptoms during the return flight home and was admitted directly to intensive care upon landing. That progression, from apparently healthy traveler to ICU patient mid-flight, has raised concerns about potential in-flight exposure to other passengers and crew.
In Nebraska, Gov. Jim Pillen confirmed that 15 passengers were transported to the National Quarantine Center, while one was admitted to the Nebraska Biocontainment Unit. The University of Nebraska Medical Center reported that 16 U.S. citizens in total were repatriated to its campus. One of those 16 had previously tested positive for Andes virus abroad and was transferred to the biocontainment unit for closer monitoring in a negative-pressure room with specialized ventilation and staff trained in advanced protective equipment.
The remaining 25 Americans under observation are at Emory University Hospital in Atlanta, where the CDC has directed additional exposed passengers, according to the agency’s situation summary. Combined with the 16 in Nebraska, that brings the total to 41 people being watched for fever, respiratory symptoms, and early signs of organ involvement. Most remain asymptomatic for now.
The quarantine timeline is long. The ECDC has outlined protocols requiring symptomatic patients to be isolated immediately, while asymptomatic passengers face monitoring periods of up to six weeks, reflecting the virus’s unpredictable incubation window, which can stretch to 42 days. For the 41 Americans, that means the watch will not end until mid-June 2026 at the earliest, tying up biocontainment beds and specialized staff well into the summer.
The gaps that remain
The most confusing open question involves whether the United States has a confirmed case. Three official accounts describe the same situation differently. The CDC’s situation summary states that no Andes virus cases have been confirmed in the United States as a result of this outbreak. The University of Nebraska Medical Center says one repatriated passenger previously tested positive. And the WHO’s updated disease outbreak notice references an inconclusive U.S. result that is under further testing.
These statements can coexist. A positive test performed in a foreign lab, an inconclusive retest at a domestic reference laboratory, and a formal designation of “no confirmed U.S. case” could all describe the same patient at different stages of the verification process. But no agency has publicly explained the discrepancy, leaving families and local health officials to interpret the silence on their own.
The total international case count is also shifting. The WHO’s May 13 update listed 11 cases and 3 deaths, with additional confirmed infections in France and Spain. But the breakdown between confirmed, probable, and inconclusive cases has changed between reporting cycles as new lab results come in. Whether any of the quarantined Americans will develop symptoms during the remaining incubation window is unknown.
Then there is the question of how efficiently the virus spread aboard the Hondius. Andes virus is unique among hantaviruses for its ability to pass between people, but the transmission dynamics on a cruise ship, where passengers share enclosed dining halls, narrow corridors, and small excursion boats, have never been studied in a setting like this. No published research specific to this outbreak yet exists. That makes it difficult to estimate how many secondary infections might still emerge.
The ship’s multi-port itinerary compounds the problem. Passengers disembarked in South Africa and scattered to their home countries before the first cases were identified. Health authorities are now relying on passenger manifests, airline records, and voluntary self-reporting to reconstruct who was near whom and for how long. Whether additional cases will surface in countries that have not yet reported infections remains a live concern for both the ECDC and WHO, which have issued guidance to member states on testing protocols. Smaller health systems with less experience identifying rare pathogens may be slower to recognize Andes virus, raising the risk of missed diagnoses.
What the coming weeks will determine
The next month will answer several questions that the current data cannot. The six-week quarantine window for the 41 Americans will close in mid-June 2026. If none develop symptoms by then, the U.S. portion of this outbreak will likely be declared contained. If some do, the Nebraska Biocontainment Unit and Emory will shift from monitoring mode to active treatment, and the CDC’s case count will change.
The French patient’s outcome on ECMO will also shape how clinicians worldwide prepare for severe Andes virus cases. ECMO is a last-resort intervention, resource-intensive and available only at specialized centers. If it proves effective here, it could influence treatment protocols for future hantavirus patients. If it does not, the outbreak’s fatality count will rise to four.
Epidemiologists will need more complete data, including patient ages, underlying health conditions, time from symptom onset to hospitalization, and access to intensive care, before drawing conclusions about whether this cruise-associated cluster is behaving differently from past Andes virus outbreaks in South America, where case fatality rates have historically ranged from roughly 20% to 40% depending on the study and the region.
Why the Hondius outbreak is still unfolding across four continents
The confirmed facts are stark. A single Antarctic cruise has seeded a multi-country outbreak of a rare and potentially lethal virus. At least one patient is fighting for his life on artificial lung support. Dozens of exposed travelers remain locked in prolonged quarantine. And official case counts are still catching up to reality. The Hondius left port carrying tourists. It returned carrying a pathogen that is now testing the limits of global disease surveillance and high-containment medicine on multiple continents at once.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
